{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:28:11Z","timestamp":1794860891761,"version":"4.9.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Preferentially expressed antigen in melanoma (PRAME) is considered a useful marker in the differential diagnosis between malignant melanoma and its melanocytic mimics. Recently PRAME expression was documented in nonmelanocytic tumors, but much of the data are based on mRNA studies. This investigation evaluated PRAME expression in the spectrum of normal tissues and &gt;5800 human tumors using immunohistochemistry and EP461 monoclonal antibody. In normal tissues, PRAME was expressed in the testis and proliferative endometrium. In tumors, PRAME was variably expressed in malignancies of different lineages. Among epithelial tumors, &gt;50% of PRAME-positive lesions were found among endometrial carcinomas (82%), uterine serous carcinomas (82%), uterine carcinosarcomas (60%), ovarian clear cell carcinomas (90%), ovarian serous carcinomas (63%), adenoid cystic carcinomas (81%), seminomas (78%), thymic carcinomas (75%), and basal cell carcinomas (62%). In mesenchymal and neuroectodermal malignancies, PRAME was frequently expressed in synovial sarcoma (71%), myxoid liposarcoma (76%), neuroblastoma (61%) and metastatic melanoma (87%). Also, PRAME was consistently expressed in 4 melanomas that lacked all melanoma markers including S100 protein and SOX10 but harbored typical for melanoma BRAF or NRAS driver mutations. However, strong and diffuse PRAME immunoreactivity was seen in many types of nonmelanocytic poorly differentiated carcinomas and sarcomas. Based on this study, PRAME is a relatively unspecific immunohistochemical marker, which limits its use in diagnostic surgical pathology. However, immunohistochemistry is a reliable and unexpensive method useful in detecting PRAME-positive malignancies for potential immunotherapy.<\/jats:p>","DOI":"10.1097\/pas.0000000000001944","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T18:06:46Z","timestamp":1660673206000},"page":"1467-1476","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":120,"title":["PRAME Expression in Cancer. A Systematic Immunohistochemical Study of &gt;5800 Epithelial and Nonepithelial Tumors"],"prefix":"10.1097","volume":"46","author":[{"given":"Maciej","family":"Kaczorowski","sequence":"first","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland"},{"name":"Department of Clinical and Experimental Pathology, Wroclaw Medical University, Wroc\u0142aw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ch\u0142opek","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kruczak","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Cracow Branch, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Ry\u015b","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Cracow Branch, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Lasota","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an nk inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/biolre\/ioab074","article-title":"The PRAME family of cancer testis antigens is essential for germline development and gametogenesis","volume":"105","author":"Kern","year":"2021","journal-title":"Biol Reprod"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/hed.20380","article-title":"Expression of cancer testis antigens in head and neck squamous cell carcinomas","volume":"28","author":"Figueiredo","year":"2006","journal-title":"Head Neck"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.oraloncology.2012.08.005","article-title":"PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions","volume":"49","author":"Szczepanski","year":"2013","journal-title":"Oral Oncol"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1038\/sj.onc.1207043","article-title":"Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes","volume":"22","author":"Boon","year":"2003","journal-title":"Oncogene"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/dna.2017.3951","article-title":"PRAME gene copy number variation is related to its expression in multiple myeloma","volume":"36","author":"Yang","year":"2017","journal-title":"DNA Cell Biol"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/1042819021000035725","article-title":"Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies","volume":"44","author":"Matsushita","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12123612","article-title":"Cancer testis antigens and immunotherapy: Expression of PRAME is associated with prognosis in soft tissue sarcoma","volume":"12","author":"Albertsmeier","year":"2020","journal-title":"Cancers"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin Sarcoma Res"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"45352","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"R14-20250612","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/ajco.12586","article-title":"Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non\u2013small cell lung cancer patients","volume":"13","author":"Pan","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"R15-20250612","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bjc.2012.215","article-title":"Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma","volume":"107","author":"Dyrskj\u00f8t","year":"2012","journal-title":"Br J Cancer"},{"key":"R16-20250612","first-page":"4090","article-title":"Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and Glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?","volume":"58","author":"Neumann","year":"1998","journal-title":"Cancer Res"},{"key":"R17-20250612","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1159\/000487353","article-title":"Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of p53 mediated pathway","volume":"45","author":"Zhu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"R18-20250612","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/his.13944","article-title":"The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma","volume":"75","author":"Xu","year":"2019","journal-title":"Histopathology"},{"key":"R19-20250612","first-page":"454","article-title":"The cancer\/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas","volume":"115","author":"Nettersheim","year":"2016","journal-title":"Br J Cancer 2016 1154"},{"key":"R20-20250612","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors","volume":"38","author":"Miettinen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R21-20250612","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/PAS.0000000000001377","article-title":"Colonic adenocarcinomas harboring ntrk fusion genes: a clinicopathologic and molecular genetic study of 16 cases and review of the literature","volume":"44","author":"Lasota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R22-20250612","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R23-20250612","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R24-20250612","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/DAD.0000000000001885","article-title":"Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms","volume":"43","author":"Googe","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"R25-20250612","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/cup.13876","article-title":"PRAME expression in 155 cases of metastatic melanoma","volume":"48","author":"Gradecki","year":"2021","journal-title":"J Cutan Pathol"},{"key":"R26-20250612","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/PAS.0000000000001645","article-title":"Dedifferentiated and undifferentiated melanomas: report of 35 new cases with literature review and proposal of diagnostic criteria","volume":"45","author":"Agaimy","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R27-20250612","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrclinonc.2017.97","article-title":"Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary","volume":"14","author":"Moran","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R28-20250612","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41379-019-0335-4","article-title":"Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas","volume":"32","author":"Toyama","year":"2019","journal-title":"Mod Pathol"},{"key":"R29-20250612","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1177\/10668969211012085","article-title":"Immunohistochemical detection of cancer-testis antigen PRAME","volume":"29","author":"Lezcano","year":"2021","journal-title":"Int J Surg Pathol"},{"key":"R30-20250612","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/cup.13812","article-title":"Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma","volume":"47","author":"Raghavan","year":"2020","journal-title":"J Cutan Pathol"},{"key":"R31-20250612","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/cup.14012","article-title":"Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin","volume":"48","author":"Elsensohn","year":"2021","journal-title":"J Cutan Pathol"},{"key":"R32-20250612","first-page":"1","article-title":"Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma","volume":"10","author":"Taniguchi","year":"2020","journal-title":"Sci Reports 2020 101"},{"key":"R33-20250612","first-page":"1","article-title":"Meta-analysis of gene expressions in testicular germ cell tumor histologies","volume":"21","author":"von E","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R34-20250612","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1073\/pnas.98.3.1176","article-title":"Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer","volume":"98","author":"Welsh","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"R35-20250612","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum Pathol"},{"key":"R36-20250612","doi-asserted-by":"crossref","first-page":"e1507600","DOI":"10.1080\/2162402X.2018.1507600","article-title":"PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy","volume":"7","author":"Luk","year":"2018","journal-title":"Oncoimmunology"},{"key":"R37-20250612","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41379-020-00687-5","article-title":"RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors","volume":"34","author":"Wang","year":"2021","journal-title":"Mod Pathol"},{"key":"R38-20250612","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cjp2.16","article-title":"Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma","volume":"1","author":"Iura","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"R39-20250612","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/modpathol.2013.244","article-title":"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma","volume":"27","author":"Hemminger","year":"2014","journal-title":"Mod Pathol"},{"key":"R40-20250612","doi-asserted-by":"crossref","first-page":"110047","DOI":"10.1016\/j.celrep.2021.110047","article-title":"Immuno-transcriptomic profiling of extracranial pediatric solid malignancies","volume":"37","author":"Brohl","year":"2021","journal-title":"Cell Rep"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:00:20Z","timestamp":1749747620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001944","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}